$1.94 Earnings Per Share Expected for Teleflex (TFX) This Quarter
Analysts expect Teleflex (NYSE:TFX) to report $1.94 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Teleflex’s earnings, with the highest EPS estimate coming in at $1.97 and the lowest estimate coming in at $1.92. Teleflex posted earnings of $1.80 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.8%. The company is scheduled to issue its next quarterly earnings results before the market opens on Thursday, May 3rd.
On average, analysts expect that Teleflex will report full-year earnings of $9.66 per share for the current financial year, with EPS estimates ranging from $9.55 to $9.88. For the next fiscal year, analysts anticipate that the firm will report earnings of $11.37 per share, with EPS estimates ranging from $11.04 to $11.97. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Teleflex.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The business had revenue of $595.10 million during the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a net margin of 7.11% and a return on equity of 16.46%. The firm’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.13 earnings per share.
Teleflex stock opened at $270.72 on Friday. The firm has a market capitalization of $11,915.08, a P/E ratio of 32.23, a price-to-earnings-growth ratio of 1.96 and a beta of 1.18. Teleflex has a 1-year low of $191.40 and a 1-year high of $288.78. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 0.89.
In other Teleflex news, Director George Babich, Jr. sold 2,500 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $283.11, for a total value of $707,775.00. Following the completion of the sale, the director now owns 9,581 shares in the company, valued at $2,712,476.91. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Benson Smith sold 9,331 shares of the stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $251.49, for a total transaction of $2,346,653.19. Following the completion of the sale, the director now owns 83,711 shares of the company’s stock, valued at approximately $21,052,479.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,721 shares of company stock valued at $9,760,009. Corporate insiders own 2.56% of the company’s stock.
A number of hedge funds have recently made changes to their positions in TFX. BlackRock Inc. lifted its stake in shares of Teleflex by 3.4% during the 4th quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock worth $1,171,779,000 after buying an additional 156,527 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Teleflex by 24.1% during the 4th quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock worth $366,912,000 after buying an additional 286,700 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Teleflex by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 398,866 shares of the medical technology company’s stock worth $99,192,000 after buying an additional 9,515 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Teleflex during the 4th quarter worth about $53,163,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Teleflex by 511.6% during the 4th quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock worth $48,694,000 after buying an additional 163,700 shares during the last quarter. Hedge funds and other institutional investors own 90.49% of the company’s stock.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.